| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
1. Anti-Aβ25-35 injury experiment: Semaglutide sodium (1-100 nM; 24 h) significantly improved the survival rate of SH-SY5Y cells, increased the expression of autophagy-related proteins such as LC3II, Atg7, Beclin-1 and P62, inhibited Bax and upregulated Bcl-2, and protected neurons by enhancing autophagy and inhibiting apoptosis [1][2]. 2. Oral squamous cell carcinoma (OSCC) cell experiment: Semaglutide sodium (5-40 μM; 48 h) dose-dependently inhibited the proliferation, migration and invasion of Cal27 and HSC4 cells, upregulated E-cadherin and downregulated vimentin, activated the P38 MAPK signaling pathway (increased p-P38 expression), and induced apoptosis [3].
|
|---|---|
| ln Vivo |
This product is not suitable for oral administration. Subcutaneous or intraperitoneal injection is recommended for animal studies. In a nude mouse oral squamous cell carcinoma (OSCC) xenograft model, semaglutide sodium (3 μmol/kg; subcutaneous injection; 3 times a week; for 3 weeks) significantly inhibited tumor growth, downregulated the proliferation markers Ki67 and PCNA, upregulated the pro-apoptotic protein Bax, downregulated the anti-apoptotic protein Bcl-xL, and induced tumor cell apoptosis by activating the p38 MAPK pathway [3]. In a chronic MPTP-induced Parkinson's disease model, semaglutide sodium (25 nmol/kg; intraperitoneal injection; every 2 days; for 30 days) improved the chronic MPTP-induced Parkinson's disease model and its motor dysfunction in mice, increased the number of tyrosine (TH) positive neurons in the substantia nigra, reduced α-synuclein aggregation and glial cell activation, and decreased the level of the oxidative stress marker 4-HNE [4]. In the metabolic dysfunction-associated fatty liver disease (MASLD) model, semaglutide (25 μg/kg/week + 100 μg/kg/week; subcutaneous injection; once a week; 11 weeks) sodium can reduce body weight, blood glucose and serum liver enzymes (ALT, AST, AP) in mice with metabolic dysfunction-associated fatty liver disease (MASLD), reduce liver triglyceride deposition, improve hepatic steatosis and hepatocyte ballooning degeneration, and downregulate de novo lipogenesis markers Acaca and Scd1[5].
|
| Cell Assay |
Cell viability assay [1][2]
Cell Types: SH-SY5Y human neuroblastoma cells Tested Concentrations: 0, 1, 10, 100 nM Incubation Duration: 24 hours Experimental Results: Cell viability: Significantly improved cell survival rate in a dose-dependent manner, reversing Aβ25-35-induced cytotoxicity. Western Blot: Upregulated autophagy markers (LC3II, Atg7, Beclin-1, P62) and anti-apoptotic protein Bcl-2, while downregulated pro-apoptotic protein Bax. |
| References |
|
| Molecular Formula |
C187H291N45O59.XNA
|
|---|---|
| Molecular Weight |
4113.58 (free base)
|
| CAS # |
2924330-56-1
|
| Sequence |
His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{C18 diacid-γ-Glu-(AEEA)2-Lys}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-GlyH-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}-EFIAWLVRGRG
|
| SequenceShortening |
H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}-EFIAWLVRGRG
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
[Na+].CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(=O)[O-])=O)CCCNC(=N)N)=O)=O)CCCNC(=N)N)=O)C(C)C)=O)CC(C)C)=O)CC1C2C(=CC=CC=2)NC=1)=O)C)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC(CNC([C@@H](NC(C(NC([C@H](CC1N=CNC=1)N)=O)(C)C)=O)CCC(=O)O)=O)=O)=O)CC1C=CC=CC=1)=O)=O)CO)=O)CC(=O)O)=O)=O)CO)=O)CO)=O)CC1C=CC(O)=CC=1)=O)CC(C)C)=O)CCC(=O)O)=O)=O)CCC(=O)N)=O)C)=O)C)=O)CCCCNC(C(C(COCCOCCN)=O)OCCOCCNC(CCCCCCCCCCCCCCCCC(=O)O)=O)=O)=O)CCC(=O)O)=O)CC1C=CC=CC=1)=O)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
